Genetic Markers for Alzheimer's Disease Resilience ID: 2014-073

This study identifies genetic markers that could help exclude unsuitable samples in clinical trials and pinpoint novel drug targets for Alzheimer's disease.

Technology Overview

This research outlines the discovery of genetic variants in genes RAB10 and SAR1A, which are linked to a reduced risk of Alzheimer's disease. Utilizing whole-genome sequencing, linkage analysis, and association studies, the study leverages data from the Cache County Study among other cohorts. It presents a significant step forward in understanding the genetic underpinnings of Alzheimer's resilience and opens new avenues for therapeutic development.

Key Advantages

• Identification of rare genetic variants associated with Alzheimer's resilience
• Advanced genomic techniques provide a comprehensive analysis of genetic data
• Potential for developing targeted therapies aimed at gene expression modification
• Contributes to more efficient and effective clinical trial sample selection

Problems Addressed

• Difficulty in identifying suitable participants for Alzheimer's disease clinical trials due to lack of genetic markers
• Limited understanding of the genetic basis of Alzheimer's disease resilience
• Challenges in finding novel, effective drug targets for Alzheimer's prevention and treatment

Market Applications

• Genetic screening tools for clinical trial participant selection
• Development of gene therapy approaches targeting RAB10 and SAR1A
• Pharmaceutical research focusing on Alzheimer's disease prevention

Additional Information

Technology ID: 2014-073
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 07 May, 2025